ATE295176T1 - Verfahren zur unterstützung der differentialdiagnostik und behandlung von autistischen syndromen - Google Patents

Verfahren zur unterstützung der differentialdiagnostik und behandlung von autistischen syndromen

Info

Publication number: ATE295176T1
Authority: AT; Austria
Prior art keywords: autistic; treatment; differential diagnosis; autistic syndrome; secretin
Prior art date: 1997-05-19

Application number

AT98924800T

Other languages

English (en)

Inventor

Karoly Horvath

Victoria Beck

Original Assignee

Repligen Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-05-19

Filing date

1998-05-19

Publication date

2005-05-15

1998-05-19 Application filed by Repligen Corp filed Critical Repligen Corp

2005-05-15 Application granted granted Critical

2005-05-15 Publication of ATE295176T1 publication Critical patent/ATE295176T1/de

Links

208000011580 syndromic disease Diseases 0.000 title abstract 5
238000003748 differential diagnosis Methods 0.000 title abstract 2
238000000034 method Methods 0.000 title 1
102100037505 Secretin Human genes 0.000 abstract 3
108010086019 Secretin Proteins 0.000 abstract 3
229960002101 secretin Drugs 0.000 abstract 3
OWMZNFCDEHGFEP-NFBCVYDUSA-N secretin human Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 abstract 3
239000008280 blood Substances 0.000 abstract 1
210000004369 blood Anatomy 0.000 abstract 1
230000000968 intestinal effect Effects 0.000 abstract 1
238000001990 intravenous administration Methods 0.000 abstract 1
230000028327 secretion Effects 0.000 abstract 1
208000024891 symptom Diseases 0.000 abstract 1
238000002560 therapeutic procedure Methods 0.000 abstract 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/121—Ketones acyclic
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2235—Secretins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/645—Secretins
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/38—Pediatrics

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Natural Medicines & Medicinal Plants (AREA)
Engineering & Computer Science (AREA)
Microbiology (AREA)
Immunology (AREA)
Biotechnology (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
Botany (AREA)
Medical Informatics (AREA)
Mycology (AREA)
Urology & Nephrology (AREA)
Alternative & Traditional Medicine (AREA)
Hematology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Bioinformatics & Cheminformatics (AREA)
Biochemistry (AREA)
Physics & Mathematics (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Pathology (AREA)
General Physics & Mathematics (AREA)
Cell Biology (AREA)
Analytical Chemistry (AREA)
Endocrinology (AREA)
Food Science & Technology (AREA)
Neurosurgery (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Neurology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)

AT98924800T 1997-05-19 1998-05-19 Verfahren zur unterstützung der differentialdiagnostik und behandlung von autistischen syndromen ATE295176T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US4704997P	1997-05-19	1997-05-19
PCT/US1998/010224 WO1998052593A1 (en)	1997-05-19	1998-05-19	Method for assisting in differential diagnosis and treatment of autistic syndromes

Publications (1)

Publication Number	Publication Date
ATE295176T1 true ATE295176T1 (de)	2005-05-15

Family

ID=21946797

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT98924800T ATE295176T1 (de)	1997-05-19	1998-05-19	Verfahren zur unterstützung der differentialdiagnostik und behandlung von autistischen syndromen

Country Status (8)

Country	Link
US (3)	US6020310A (de)
EP (1)	EP1019072B1 (de)
JP (1)	JP2002501616A (de)
AT (1)	ATE295176T1 (de)
AU (1)	AU748147B2 (de)
CA (1)	CA2290556A1 (de)
DE (1)	DE69830185D1 (de)
WO (1)	WO1998052593A1 (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6150321A (en) *	1996-12-12	2000-11-21	Colgate-Palmolive Co.	Chemical linker compositions
US6020310A (en)	1997-05-19	2000-02-01	Repligen Corporation	Method for assisting in differential diagnosis and treatment of autistic syndromes
US6197746B1 (en) *	1998-05-19	2001-03-06	Repligen Corporation	Method of using secretin for treating autism
US6020314A (en) *	1998-08-11	2000-02-01	Milkhaus Laboratory, Inc.	Methods for treatment of neurological disorders
DE19902773A1 (de) *	1999-01-25	2000-07-27	Sertuerner Arzneimittel Gmbh	Anticholestatische Wirksamkeit von Luteolin
US6552000B2 (en) *	1999-02-08	2003-04-22	Ortho-Mcneil Pharmaceutical, Inc.	Anticonvulsant derivatives useful in treating autism
WO2000068433A2 (en) *	1999-05-06	2000-11-16	Children's Hospital Of Los Angeles	Autism gene
WO2001032199A1 (en)	1999-11-05	2001-05-10	Rogoff Joseph A	Secretin and secretin pharmaceuticals for treating lactose intolerance
DE19953339A1 (de) *	1999-11-05	2001-05-17	Goldham Pharma Gmbh	Secretinfragmente
US6632429B1 (en)	1999-12-17	2003-10-14	Joan M. Fallon	Methods for treating pervasive development disorders
US6534063B1 (en)	1999-12-17	2003-03-18	Joan M. Fallon	Methods for treating pervasive development disorders
WO2001079837A1 (en) *	2000-04-12	2001-10-25	Repligen Corporation	Methylxanthines in the diagnosis and treatment of autistic disorder
GB0016441D0 (en) *	2000-07-04	2000-08-23	Pharmagene Lab Limited	Therapeutic method
US20070053895A1 (en)	2000-08-14	2007-03-08	Fallon Joan M	Method of treating and diagnosing parkinsons disease and related dysautonomic disorders
US6660831B2 (en) *	2000-08-14	2003-12-09	Joan M. Fallon	Method for diagnosing and treating dysautonomia and other dysautonomic conditions
US8030002B2 (en)	2000-11-16	2011-10-04	Curemark Llc	Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
WO2003028668A2 (en) *	2001-10-04	2003-04-10	Protein Therapeutics, Inc.	Gammaglobulin treatment of immune disorders
US8100844B2 (en) *	2002-04-25	2012-01-24	Ultraflex Systems, Inc.	Ambulating ankle and knee joints with bidirectional dampening and assistance using elastomeric restraint
US8524665B2 (en) *	2003-05-13	2013-09-03	The Mclean Hospital Corporation	Use of secretin in treatments of disorders associated with the amygdala
JP2005082490A (ja) *	2003-09-04	2005-03-31	Kirin Brewery Co Ltd	脳機能改善剤
US7381698B2 (en) *	2003-12-12	2008-06-03	Chirhoclin, Inc.	Methods for treatment of acute pancreatitis
US7947285B2 (en) *	2003-12-12	2011-05-24	Fein Seymour H	Methods for preventing post endoscopic retrograde cholangiopancreatography pancreatitis
US20060198838A1 (en) *	2004-09-28	2006-09-07	Fallon Joan M	Combination enzyme for cystic fibrosis
US20080058282A1 (en)	2005-08-30	2008-03-06	Fallon Joan M	Use of lactulose in the treatment of autism
US20070116695A1 (en) *	2005-09-21	2007-05-24	Fallon Joan M	Pharmaceutical preparations for attention deficit disorder, attention deficit hyperactivity disorder and other associated disorders
US8551986B2 (en) *	2005-12-08	2013-10-08	The Mclean Hospital Corporation	Treatment of sequelae of psychiatric disorders
US8658163B2 (en)	2008-03-13	2014-02-25	Curemark Llc	Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en)	2008-04-18	2011-12-27	Curemark Llc	Method for the treatment of the symptoms of drug and alcohol addiction
US9320780B2 (en) *	2008-06-26	2016-04-26	Curemark Llc	Methods and compositions for the treatment of symptoms of Williams Syndrome
US20090324730A1 (en) *	2008-06-26	2009-12-31	Fallon Joan M	Methods and compositions for the treatment of symptoms of complex regional pain syndrome
PL2318035T3 (pl)	2008-07-01	2019-10-31	Curemark Llc	Sposoby i kompozycje do leczenia objawów zaburzeń neurologicznych i zaburzeń zdrowia psychicznego
US10776453B2 (en) *	2008-08-04	2020-09-15	Galenagen, Llc	Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
US20100092447A1 (en)	2008-10-03	2010-04-15	Fallon Joan M	Methods and compositions for the treatment of symptoms of prion diseases
CA2747703C (en)	2009-01-06	2021-06-15	Curemark Llc	Compositions and methods for the treatment or the prevention of infections by e. coli
JP5684725B2 (ja)	2009-01-06	2015-03-18	キュレロンリミテッドライアビリティカンパニー	黄色ブドウ球菌感染の治療または予防のための組成物および方法ならびに表面上にいる黄色ブドウ球菌の根絶または低減のための組成物および方法
US9056050B2 (en)	2009-04-13	2015-06-16	Curemark Llc	Enzyme delivery systems and methods of preparation and use
EP2443259A4 (de) *	2009-06-16	2012-10-10	Univ Columbia	Biomarker für autismus und verwendungen davon
US9050276B2 (en)	2009-06-16	2015-06-09	The Trustees Of Columbia University In The City Of New York	Autism-associated biomarkers and uses thereof
US9511125B2 (en)	2009-10-21	2016-12-06	Curemark Llc	Methods and compositions for the treatment of influenza
EP2493471B1 (de)	2009-10-26	2019-11-27	Thomas Julius Borody	Neue enterale kombinationstherapie
RU2460466C2 (ru) *	2010-10-28	2012-09-10	Федеральное государственное учреждение "Российский научный центр восстановительной медицины и курортологии Федерального агентства по здравоохранению и социальному развитию РФ" (ФГУ "РНЦВМиК Росздрава")	Способ определения уровня нервно-психического развития ребенка первого года жизни
US8586384B2 (en) *	2011-04-05	2013-11-19	Olympus Corporation	Method of collecting duodenal specimen to detect upper digestive system disease without using pancreatic or bile stimulant
EP2696202B1 (de)	2011-04-05	2017-09-06	Olympus Corporation	Bauchspeicheldrüsentestverfahren und bauchspeicheldrüsentestkit
US8529547B2 (en) *	2011-04-05	2013-09-10	Olympus Corporation	Method of collecting specimen and method of diagnosing subject to detect upper digestive system disease
DK2701733T3 (da)	2011-04-21	2019-05-27	Curemark Llc	Forbindelser til behandling af neuropsykiatriske forstyrrelser
US10039777B2 (en)	2012-03-20	2018-08-07	Neuro-Lm Sas	Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
US10350278B2 (en)	2012-05-30	2019-07-16	Curemark, Llc	Methods of treating Celiac disease
WO2015001831A1 (ja) *	2013-07-02	2015-01-08	オリンパス株式会社	膵疾患マーカー検出用十二指腸液試料の決定方法、及び膵疾患マーカーの検出方法
WO2018191233A1 (en)	2017-04-10	2018-10-18	Curemark, Llc	Compositions for treating addiction
US11464789B2 (en)	2018-08-03	2022-10-11	Enterin, Inc.	Aminosterol compositions and methods of using the same for treating schizophrenia
CN109182577B (zh) *	2018-09-25	2022-03-15	深圳市英马诺生物科技有限公司	自闭症生物标志物及其应用
US11541009B2 (en)	2020-09-10	2023-01-03	Curemark, Llc	Methods of prophylaxis of coronavirus infection and treatment of coronaviruses

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3833722A (en)	1971-03-16	1974-09-03	D Graybill	Method for controlling allergies
JPS5029005B2 (de) *	1972-05-08	1975-09-19
US3987014A (en) *	1974-01-10	1976-10-19	Becton, Dickinson And Company	Secretin intermediates and derivatives
DE2615229C2 (de) *	1976-04-08	1984-05-24	Hoechst Ag, 6230 Frankfurt	Verfahren zur Herstellung und Reinigung von Sekretin
US4086220A (en) *	1976-08-09	1978-04-25	G. D. Searle & Co.	Fragments of secretin
EP0021184B1 (de) *	1979-06-13	1984-02-08	Hoechst Aktiengesellschaft	Sekretinpräparate mit verstärkter und protrahierter Wirkung, Verfahren zu ihrer Herstellung sowie Dihydroxybenzoyl-L-tyrosin
NZ196349A (en)	1980-03-07	1984-08-24	Interx Research Corp	Enhancement of absorption rate of orally administered polar bioactive agents
JPS58140024A (ja) *	1982-02-15	1983-08-19	Eisai Co Ltd	セクレチンの精製方法
DE3328793A1 (de) *	1983-08-10	1985-02-28	Hoechst Ag, 6230 Frankfurt	Herstellung von sekretin
SE454513B (sv) *	1985-03-11	1988-05-09	Kabigen Ab	Humant sekretin samt kompositioner innehallande detta
JPS61277618A (ja) *	1985-06-04	1986-12-08	Suntory Ltd	自閉症治療剤
US5008251A (en) *	1986-03-27	1991-04-16	The Regents Of The University Of California	Method of treating autism
US4994467A (en) *	1989-05-31	1991-02-19	Zimmerman Andrew W	Treating autism and other developmental disorders in children with NMDA receptor antagonists
US5094837A (en) *	1990-01-22	1992-03-10	Wayne State University	Method for use of magnetic resonance imaging to image pancreas using secretin
US5225407A (en) *	1990-02-22	1993-07-06	Glaxo Group Limited	5-HT3 receptor antagonists for the treatment of autism
US5380872A (en)	1992-07-14	1995-01-10	Glaxo Inc.	Modulators of cholecystokinin
ES2154673T3 (es)	1993-01-29	2001-04-16	Aradigm Corp	Suministro intrapulmonar de hormonas.
US5527825A (en) *	1994-04-06	1996-06-18	University Of Arkansas	Method of treating schizophrenia, tourette's syndrome, mania, autism, and obsessive compulsive disorder with inhibitors of brain nitric oxide synthase
GB9417524D0 (en)	1994-08-31	1994-10-19	Cortecs Ltd	Pharmaceutical compositions
US5686311A (en) *	1995-06-23	1997-11-11	The Children's Mercy Hospital	Diagnosis of autism and treatment therefor
US6197746B1 (en) *	1998-05-19	2001-03-06	Repligen Corporation	Method of using secretin for treating autism
US6020310A (en) *	1997-05-19	2000-02-01	Repligen Corporation	Method for assisting in differential diagnosis and treatment of autistic syndromes
FR2767830B1 (fr)	1997-08-26	2000-02-04	Sod Conseils Rech Applic	Oligonucleotides permettant l'identification de precurseurs d'hormones polypeptidiques amidees

1998
- 1998-05-19 US US09/080,631 patent/US6020310A/en not_active Expired - Fee Related
- 1998-05-19 JP JP55052798A patent/JP2002501616A/ja not_active Ceased
- 1998-05-19 DE DE69830185T patent/DE69830185D1/de not_active Expired - Fee Related
- 1998-05-19 AT AT98924800T patent/ATE295176T1/de not_active IP Right Cessation
- 1998-05-19 EP EP98924800A patent/EP1019072B1/de not_active Expired - Lifetime
- 1998-05-19 AU AU76885/98A patent/AU748147B2/en not_active Ceased
- 1998-05-19 WO PCT/US1998/010224 patent/WO1998052593A1/en not_active Ceased
- 1998-05-19 CA CA002290556A patent/CA2290556A1/en not_active Abandoned
1999
- 1999-11-24 US US09/449,512 patent/US6498143B1/en not_active Expired - Fee Related
2002
- 2002-12-20 US US10/327,591 patent/US7091182B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
WO1998052593A1 (en)	1998-11-26
DE69830185D1 (de)	2005-06-16
JP2002501616A (ja)	2002-01-15
EP1019072A1 (de)	2000-07-19
US7091182B2 (en)	2006-08-15
US6498143B1 (en)	2002-12-24
EP1019072B1 (de)	2005-05-11
US20040146495A1 (en)	2004-07-29
EP1019072A4 (de)	2002-06-19
AU7688598A (en)	1998-12-11
US6020310A (en)	2000-02-01
AU748147B2 (en)	2002-05-30
CA2290556A1 (en)	1998-11-26

Legal Events

Date	Code	Title	Description
2005-11-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE69830185D1 (de)	2005-06-16	Verfahren zur unterstützung der differentialdiagnostik und behandlung von autistischen syndromen
ATE204178T1 (de)	2001-09-15	Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
NO20002005L (no)	2000-05-16	FremgangsmÕte for behandling av hyperkoagulable tilstander eller protein C mangel
BG60253B1 (bg)	1994-03-24	Човешки тъканен плазминогенен активатор
ATE185268T1 (de)	1999-10-15	Fortschrittliches arzneistoffabgabesystem und verfahren zur behandlung von psychiatrischen, neurologischen und anderen erkrankungen mit carbamazepin
SE8501050D0 (sv)	1985-03-05	Biologically active fragments of human antihemophilic factor and method for preparation thereof
DE69930739D1 (de)	2006-05-18	Transdermale verwendung von sekretin zur behandlung von autismus
DE69333321D1 (de)	2004-01-08	Verwendung eines Consensus-Interferons zur Reduzierung der Nebeneffekte in der Interferon Behandlung von viralen Hepatiten.
ATE209908T1 (de)	2001-12-15	RADIKALFÄNGER (ßSPIN TRAPSß) ZUR BEHANDLUNG VON MIT OXIDATION VON LIPIDEN UND PROTEINEN VERBUNDENEN ERKRANKUNGEN
ATE66374T1 (de)	1991-09-15	Zubereitungen und verfahren zur behandlung von blutungsstoerungen.
EA200401070A1 (ru)	2005-02-24	Способы лечения сосудистых заболеваний
BG49827A3 (bg)	1992-02-14	Метод за получаване на пречистен биологично активен рекомбинантен човешки колоний стимулиращ фактор
DE3685853D1 (de)	1992-08-06	Mittel zur behandlung von knochenkrankheiten.
KR950031063A (ko)	1995-12-18	프라바스타틴을 이용하여 관상 동맥 아테롬성 동맥경화증의 진행 속도를 감소시키는 방법
FI953565A7 (fi)	1995-07-26	Uusi antikoagulanttikofaktoriaktiivisuus
ATE44156T1 (de)	1989-07-15	Kovalent gebundener heparin-antithrombin iiikomplex, verfahren zu dessen herstellung und seine verwendung zur behandlung von thrombusembolie.
DE69625682D1 (de)	2003-02-13	Verfahren zur behandlung von entzündungen und zusammensetzungen dafür
DE69822810D1 (de)	2004-05-06	Somatostatin und somatostatin agoniste zur behandlung der insulinsunempfindlichkeit und syndrome x
DE69621786D1 (de)	2002-07-18	Aminotetralinderivat zur behandlung von herzkreislauferkrankung
ATE293994T1 (de)	2005-05-15	Multivalente rekombinante antikörper zur behandlung von hrv infektionen
ATE295731T1 (de)	2005-06-15	Olanzapine zur behandlung von drogenmissbrauch
DE3650368D1 (de)	1995-09-21	Verwendung von Depogen zur Behandlung von eingeschränktem Blutkreislauf.
RU93000004A (ru)	1996-09-20	Вещество для лечения подкожной фибрасаркомы и способ его получения
RU2043103C1 (ru)	1995-09-10	Средство, уменьшающее внешнесекреторную недостаточность поджелудочной железы при хроническом панкреатите
NO961180L (no)	1996-03-22	Transdermal anordning inneholdende (E)-2-(p-fluorfenetyl)-3-fluorallylamin for behandling av Alzheimers sykdom